CETP protein, human
NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations
NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease